The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and goals for assessing important and salient issues for medications development in alcohol use disorders

Neuropsychopharmacology

Volumn 37, Issue 2, 2012, Pages 402-411

  Anton, Raymond F ^a   Litten, Raye Z ^b   Falk, Daniel E ^b   Palumbo, Joseph M ^c   Bartus, Raymond T ^d   Robinson, Rebecca L ^e   Kranzler, Henry R ^f   Kosten, Thomas R ^g   Meyer, Roger E ^h   O'Brien, Charles P ^f   Mann, Karl ⁱ   Meulien, Didier ^j  

^a MUSC Center for Drug and Alcohol Programs   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d Ceregene   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Best Practice Management   (United States)

ⁱ CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^j Lundbeck   (France)

more..

Author keywords

addiction and substance abuse; alcohol and alcoholism; clinical pharmacology clinical trials; drug discovery development; neuropharmacology

Indexed keywords

ACAMPROSATE; ALCOHOL; BIOLOGICAL MARKER; DRUGS USED IN THE TREATMENT OF ADDICTION; NALTREXONE; PLACEBO;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DATA ANALYSIS; DRINKING BEHAVIOR; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HUMAN; MEDICAL EXPERT; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SELF REPORT;

ALCOHOLISM; CLINICAL TRIALS AS TOPIC; CONSENSUS; DRUG DISCOVERY; GOALS; HUMANS; SELF REPORT;

EID: 84856050408     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.182     Document Type: Review

References (25)

1. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J (2008). A randomized, multicenter, double-blind, placebocontrolled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28: 5-12.
2. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combine Study Research Group: combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003-2017. (Pubitemid 44794003)
3. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31: 5-19. (Pubitemid 41214353)
4. Cisler RA, Zweben A (1999). Development of a composite measure for assessing alcohol treatment outcome: operationalization and validation. Alcohol Clin Exp Res 23: 263-271. (Pubitemid 29100400)
5. Fleming M, Mundt M (2004). Carbohydrate-deficient transferrin: validity of a new alcohol biomarker in a sample of patients with diabetes and hypertension. J Am Board Fam Pract 17: 247-255.
6. Garbutt J, Kranzler H, O'Malley S, Gastfriend D, Pettinati H, Silverman B et al (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA 293: 1617-1625. (Pubitemid 40471792)
7. Hasin DS, Stinson FS, Ogburn E, Grant BF (2007). Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 64: 830-842. (Pubitemid 47026379)
8. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K et al (2008). Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168: 1188-1199. (Pubitemid 351831402)
9. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K et al (2007). Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298: 1641-1651. (Pubitemid 47606653)
10. Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ (1993). Alcoholism and major depression in women. Arch Gen Psychiatry 50: 690-698.
11. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001). Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734-1739.
12. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR (2009). Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99: 345-349.
13. Miller PM, Anton R (2004). Biochemical alcohol screening in primary health care. Addict Behav 29: 1427-1437. (Pubitemid 39165998)
14. Miller WR, Tonigan JS, Longabaugh R (1995). The Drinker Inventory of Consequences (DrInC). An Instrument for Assessing Adverse Consequences of Alcohol Abuse (Test Manual). U. S. Department of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism: Bethesda, MD. DHHS Pub. No. 95-3911.
15. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
16. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373: 2223-2233.
17. Schuckit MA, Tipp JE, Smith TL, Bucholz KK (1997). Periods of abstinence following the onset of alcohol dependence in 1853 men and women. J Stud Alcohol 58: 581-589. (Pubitemid 27498053)
18. Skinner HA, Horn JL (1984). Alcohol Dependence Scale: Users Guide. Addiction Research Foundation: Toronto.
19. Sobell LC, Brown J, Leo GI, Sobell MB (1996). The reliability of the alcohol timeline follow back when administered by telephone and by computer. Drug Alcohol Depend 42: 49-54. (Pubitemid 26300639)
20. Sobell LC, Sobell MB, Leo GI, Cancilla A (1988). Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83: 393-402.
21. Stewart SH, Latham PK, Miller PM, Randall P, Anton RF (2008). Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction 103: 1622-1628.
22. Substance Abuse and Mental Health Services Administration (2004). Results from the 2003 National Survey on Drug Use and Health: National Findings SAMHSA 2004 ed. Office of Applied Studies: Rockville, MD, NSDUH Series H-25, DHHS Publication No. SMA 04-3694.
23. Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB et al. (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106: 337-345. (Pubitemid 37505881)
24. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
25. Zweben A, Cisler RA (2003). Clinical and methodological utility of a composite outcome measure for alcohol treatment research. Alcohol Clin Exp Res 27: 1680-1685. (Pubitemid 37280752)